Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
McKinsey
Harvard Business School
Dow

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR MYRBETRIQ


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Myrbetriq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00410514 ↗ A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Completed Astellas Pharma Inc Phase 2 2006-12-01 This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
NCT00688688 ↗ Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-25 The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
NCT00689104 ↗ Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-28 The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Myrbetriq

Condition Name

Condition Name for Myrbetriq
Intervention Trials
Overactive Bladder 14
Urinary Bladder, Overactive 5
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Myrbetriq
Intervention Trials
Urinary Bladder, Overactive 25
Urologic Diseases 6
Urinary Bladder Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Myrbetriq

Trials by Country

Trials by Country for Myrbetriq
Location Trials
United States 243
Canada 47
Germany 15
Hungary 12
Poland 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Myrbetriq
Location Trials
Maryland 11
California 10
New York 10
Massachusetts 9
Florida 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Myrbetriq

Clinical Trial Phase

Clinical Trial Phase for Myrbetriq
Clinical Trial Phase Trials
Phase 4 11
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Myrbetriq
Clinical Trial Phase Trials
Completed 30
Recruiting 5
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Myrbetriq

Sponsor Name

Sponsor Name for Myrbetriq
Sponsor Trials
Astellas Pharma Europe B.V. 8
Astellas Pharma Inc 7
Astellas Pharma Global Development, Inc. 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Myrbetriq
Sponsor Trials
Other 31
Industry 29
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
AstraZeneca
McKinsey
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.